Ratings by JPMorgan (Anupam Rama)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
6/11/2021 Protagonist Therapeutics PTGX Maintain Overweight
(N/A)
 
 
  Details
6/2/2021 Constellation Pharmaceuticals CNST Downgrade Neutral
(Overweight)
20.24
(33.73)
66.65% Details
6/1/2021 Orchard Therapeutics ORTX Maintain Overweight
(N/A)
 
 
  Details
5/14/2021 iTeos Therapeutics ITOS Maintain Overweight
(N/A)
 
 
  Details
5/13/2021 Atara Biotherapeutics ATRA Upgrade Overweight
(Neutral)
13.91
(14.40)
3.52% Details
5/12/2021 Spring Works Therapeutics SWTX Maintain Overweight
(N/A)
 
 
  Details
5/11/2021 Oyster Point Pharma OYST Maintain Overweight
(N/A)
 
 
  Details
5/11/2021 Kodiak Sciences Inc. KOD Maintain Neutral
(N/A)
 
 
  Details
5/11/2021 Allovir Inc. ALVR Maintain Overweight
(N/A)
 
 
  Details
5/7/2021 Mirati Therapeutics MRTX Maintain Overweight
(N/A)
 
 
  Details
5/7/2021 ChemoCentryx CCXI Downgrade Underweight
(Neutral)
27.49
(12.18)
-55.69% Details
5/6/2021 Neurocrine Bio. NBIX Maintain Neutral
(N/A)
 
 
  Details
5/6/2021 Theravance Biopharma TBPH Maintain Overweight
(N/A)
 
 
  Details
5/6/2021 AnaptysBio ANAB Maintain Underweight
(N/A)
 
 
  Details
5/6/2021 Atara Biotherapeutics ATRA Maintain Neutral
(N/A)
 
 
  Details
4/16/2021 Ideaya Biosciences IDYA Maintain Overweight
(N/A)
 
 
  Details
3/29/2021 CytomX Therapeutics CTMX New Coverage Overweight
(N/A)
7.94
(7.16)
-9.82% Details
3/23/2021 Frequency Therapeutics FREQ Downgrade Underweight
(Overweight)
36.29
(9.64)
-73.44% Details
3/19/2021 Olema Pharmaceuticals OLMA Maintain Overweight
(N/A)
 
 
  Details
3/19/2021 Idera Pharmaceuticals IDRA Downgrade Neutral
(Overweight)
5.13
(1.31)
-74.46% Details
3/8/2021 AnaptysBio ANAB Downgrade Underweight
(Overweight)
29.47
(24.28)
-17.61% Details
3/2/2021 Orchard Therapeutics ORTX New Coverage Overweight
(N/A)
6.97
(5.12)
-26.54% Details
2/22/2021 BridgeBio Pharma BBIO New Coverage Overweight
(N/A)
63.85
(63.93)
0.13% Details
2/16/2021 G1 Therapeutics GTHX Maintain Overweight
(N/A)
 
 
  Details
2/11/2021 AnaptysBio ANAB Upgrade Overweight
(Neutral)
29.61
(29.47)
-0.47% Details
2/5/2021 Infinity Pharmaceutical INFI Upgrade Neutral
(Underweight)
3.70
(3.45)
-6.76% Details
1/27/2021 Frequency Therapeutics FREQ Upgrade Overweight
(Neutral)
37.83
(36.29)
-4.07% Details
1/27/2021 Vir Biotechnology VIR Downgrade Underweight
(Neutral)
44.39
(45.53)
2.57% Details
1/8/2021 Sarepta Therapeutics SRPT Downgrade Underweight
(Overweight)
168.95
(86.00)
-49.1% Details
1/4/2021 Passage Bio Inc. PASG Upgrade Overweight
(Neutral)
25.57
(14.11)
-44.82% Details
11/30/2020 Kodiak Sciences Inc. KOD Downgrade Neutral
(Overweight)
132.20
(83.62)
-36.75% Details
11/10/2020 Neurocrine Bio. NBIX Maintain Neutral
(N/A)
 
 
  Details
11/6/2020 Oyster Point Pharma OYST Maintain Overweight
(N/A)
 
 
  Details
10/29/2020 ChemoCentryx CCXI Downgrade Neutral
(Overweight)
52.44
(12.18)
-76.77% Details
10/5/2020 MyoKardia MYOK Downgrade Neutral
(Overweight)
139.60
(224.91)
61.11% Details
9/11/2020 Vir Biotechnology VIR Upgrade Neutral
(Underweight)
30.17
(45.53)
50.91% Details
8/25/2020 Sarepta Therapeutics SRPT Maintain Overweight
(N/A)
 
 
  Details
8/24/2020 Allovir Inc. ALVR New Coverage Overweight
(N/A)
30.85
(22.05)
-28.53% Details
8/17/2020 Annexon Biosciences ANNX New Coverage Overweight
(N/A)
26.17
(23.85)
-8.87% Details
8/17/2020 iTeos Therapeutics ITOS New Coverage Overweight
(N/A)
31.40
(20.03)
-36.21% Details
8/14/2020 Passage Bio Inc. PASG Downgrade Neutral
(Overweight)
14.77
(25.57)
73.12% Details
8/13/2020 Spring Works Therapeutics SWTX Maintain Overweight
(N/A)
 
 
  Details
8/11/2020 ChemoCentryx CCXI Maintain Overweight
(N/A)
 
 
  Details
8/11/2020 Generation Bio GBIO Maintain Neutral
(N/A)
 
 
  Details
8/5/2020 MyoKardia MYOK Maintain Overweight
(N/A)
 
 
  Details
8/5/2020 Oyster Point Pharma OYST Maintain Overweight
(N/A)
 
 
  Details
8/4/2020 Neurocrine Bio. NBIX Downgrade Neutral
(Overweight)
120.36
(98.61)
-18.07% Details
7/17/2020 Kiniksa KNSA Maintain Overweight
(N/A)
 
 
  Details
7/13/2020 Ideaya Biosciences IDYA Upgrade Overweight
(Neutral)
13.34
(20.89)
56.6% Details
7/7/2020 Generation Bio GBIO New Coverage Overweight
(N/A)
19.56
(27.00)
38.04% Details
7/7/2020 Theravance Biopharma TBPH New Coverage Overweight
(N/A)
20.52
(18.20)
-11.31% Details
6/29/2020 Kiniksa KNSA Maintain Overweight
(N/A)
 
 
  Details
5/18/2020 Frequency Therapeutics FREQ Downgrade Neutral
(Overweight)
16.99
(37.83)
122.66% Details
5/14/2020 Eidos Therapeutics EIDX Downgrade Neutral
(Overweight)
41.09
(122.21)
197.42% Details
5/7/2020 Alnylam Pharmaceuticals ALNY Downgrade Neutral
(Overweight)
141.23
(165.02)
16.84% Details
5/1/2020 Mirati Therapeutics MRTX Upgrade Overweight
(Neutral)
87.80
(172.04)
95.95% Details
3/24/2020 Passage Bio Inc. PASG New Coverage Overweight
(N/A)
9.79
(14.11)
44.13% Details
3/20/2020 Zai Lab ZLAB Maintain Overweight
(N/A)
 
 
  Details
3/19/2020 Vir Biotechnology VIR Downgrade Underweight
(Neutral)
50.26
(45.53)
-9.41% Details
3/18/2020 Spring Works Therapeutics SWTX Maintain Overweight
(N/A)
 
 
  Details
3/17/2020 Kodiak Sciences Inc. KOD Maintain Overweight
(N/A)
 
 
  Details
3/12/2020 Mirati Therapeutics MRTX Upgrade Neutral
(Underweight)
86.58
(87.80)
1.41% Details
3/2/2020 BridgeBio Pharma BBIO Maintain Overweight
(N/A)
 
 
  Details
2/18/2020 ChemoCentryx CCXI Maintain Overweight
(N/A)
 
 
  Details
2/13/2020 Agios Pharma AGIO Maintain Overweight
(N/A)
 
 
  Details
2/4/2020 Vir Biotechnology VIR Downgrade Neutral
(Overweight)
26.63
(50.26)
88.73% Details
12/24/2019 Kodiak Sciences Inc. KOD New Coverage Overweight
(N/A)
67.03
(83.62)
24.75% Details
12/24/2019 Y-mAbs Therapeutics YMAB New Coverage Overweight
(N/A)
31.75
(36.29)
14.3% Details
12/5/2019 Audentes Therapeutics BOLD Downgrade Neutral
(Overweight)
59.30
(59.97)
1.13% Details
11/26/2019 ChemoCentryx CCXI Maintain Overweight
(N/A)
 
 
  Details
11/25/2019 Alnylam Pharmaceuticals ALNY Maintain Overweight
(N/A)
 
 
  Details
11/22/2019 Apellis Pharmaceuticals APLS Maintain Overweight
(N/A)
 
 
  Details
11/8/2019 AnaptysBio ANAB Downgrade Underweight
(Overweight)
36.16
(24.28)
-32.85% Details
11/8/2019 Atara Biotherapeutics ATRA Downgrade Neutral
(Overweight)
12.16
(14.40)
18.42% Details
11/5/2019 Vir Biotechnology VIR New Coverage Overweight
(N/A)
15.00
(45.53)
203.53% Details
10/28/2019 Frequency Therapeutics FREQ New Coverage Overweight
(N/A)
14.05
(9.64)
-31.39% Details
10/16/2019 Mirati Therapeutics MRTX Maintain Underweight
(N/A)
 
 
  Details
10/8/2019 Spring Works Therapeutics SWTX New Coverage Overweight
(N/A)
18.15
(82.22)
353% Details
10/3/2019 Dova Pharmaceuticals Inc DOVA Upgrade Neutral
(Underweight)
27.87
(28.04)
0.61% Details
9/12/2019 ChemoCentryx CCXI Upgrade Overweight
(Neutral)
7.59
(12.18)
60.47% Details
8/8/2019 G1 Therapeutics GTHX Upgrade Overweight
(Neutral)
23.48
(21.62)
-7.92% Details
8/2/2019 Mirati Therapeutics MRTX New Coverage Underweight
(N/A)
105.80
(172.04)
62.61% Details
7/12/2019 Replimune Group REPL Upgrade Overweight
(Neutral)
13.93
(34.00)
144.08% Details
7/12/2019 Apellis Pharmaceuticals APLS Upgrade Overweight
(Neutral)
26.88
(62.12)
131.1% Details
4/22/2019 Neurocrine Bio. NBIX Upgrade Overweight
(Neutral)
78.43
(98.61)
25.73% Details
4/17/2019 Mirati Therapeutics MRTX New Coverage Neutral
(N/A)
65.18
(105.80)
62.32% Details
3/21/2019 Aeglea Biotherapeutics AGLE New Coverage Overweight
(N/A)
8.25
(6.60)
-20% Details
3/1/2019 Rigel Pharmaceuticals RIGL Maintain Overweight
(N/A)
 
 
  Details
2/27/2019 Eidos Therapeutics EIDX Upgrade Overweight
(Neutral)
17.51
(122.21)
597.94% Details
2/21/2019 Zai Lab ZLAB Maintain Overweight
(N/A)
 
 
  Details
1/23/2019 Replimune Group REPL Downgrade Neutral
(Overweight)
10.45
(13.93)
33.3% Details
1/23/2019 Neurocrine Bio. NBIX Downgrade Neutral
(Overweight)
91.53
(78.43)
-14.31% Details
1/23/2019 La Jolla Pharma LJPC Upgrade Neutral
(Underweight)
6.30
(5.12)
-18.73% Details
1/23/2019 G1 Therapeutics GTHX Downgrade Neutral
(Overweight)
20.13
(23.48)
16.64% Details
1/23/2019 Eidos Therapeutics EIDX Downgrade Neutral
(Overweight)
12.65
(17.51)
38.42% Details
1/23/2019 Dova Pharmaceuticals Inc DOVA Downgrade Underweight
(Overweight)
8.23
(27.87)
238.64% Details
1/23/2019 Apellis Pharmaceuticals APLS Downgrade Neutral
(Overweight)
13.44
(26.88)
100% Details
12/12/2018 Neurocrine Bio. NBIX Maintain Overweight
(Overweight)
 
 
  Details
11/26/2018 Orchard Therapeutics ORTX New Coverage Overweight
(N/A)
16.04
(5.12)
-68.08% Details
11/26/2018 Audentes Therapeutics BOLD New Coverage Overweight
(N/A)
24.01
(59.30)
146.98% Details
11/21/2018 AnaptysBio ANAB New Coverage Overweight
(N/A)
67.80
(36.16)
-46.67% Details
11/12/2018 Infinity Pharmaceutical INFI Downgrade Underweight
(Neutral)
2.41
(3.45)
43.15% Details
10/8/2018 Dynavax Technologies DVAX Maintain Overweight
(Overweight)
 
 
  Details
8/27/2018 Eidos Therapeutics EIDX Maintain Overweight
(N/A)
 
 
  Details
8/15/2018 Idera Pharmaceuticals IDRA New Coverage Overweight
(N/A)
7.39
(1.31)
-82.27% Details
8/14/2018 Replimune Group REPL New Coverage Overweight
(N/A)
16.91
(10.45)
-38.2% Details
8/14/2018 ChemoCentryx CCXI Downgrade Neutral
(Overweight)
11.95
(7.59)
-36.49% Details
8/13/2018 Constellation Pharmaceuticals CNST New Coverage Overweight
(N/A)
9.87
(20.24)
105.07% Details